Since the initial description of the diverticulosis of the colon in mid-1800, these saccular protrusions of the mucosa and submucosa of the colon through the bowel wall have progressively assumed more clinical importance over the 20th century and has become a common gastroenterological problem in the aging population.
There is no controversy that H. Pylori (HP) causes gastritis. However, to date, there is no direct evidence that HP causes any ulcers. There is good statistical correlation between ulcer diseases and HP yet statistical correlation does not imply causality. HP induced gastritis is associated with hypochlorohydria and increased bicarbonate secretion seen with gastric ulcer (GU). Low acid and high bicarbonate secretion associated with HP has been found to be protective against the development of reflux oesophagitis (GORD). This is believed to be the reason why GORD develops for the first time after eradication of HP for duodenal ulcers (DU)(1).Despite greater than 90% correlation of HP and DU, paradoxically acid secretion is increased and bicarbonate secretion is decreased in DU. Yet HP eradication reduces relapse of DU although not to the extent it was believed in the past. Recent meta-analysis of randomized trials indicate a relapse rate of 20% of DU 6 months after HP eradication(2).So what shall we do? The following are my suggestions:
ERCP is essentially a therapeutic procedure for the management of mainly biliary and to a lesser extent pancreatic disorders. ERCP mostly involves a sphincterotomy ( a cut ) to open the duodenal ampulla to remove stones from the bile duct, stenting of bile duct to relieve obstruction from inoperable cholangiocarcinoma , pancreatic cancer or metastatic tumour, removal of pancreatic duct stone, obtain brush cytology from probable malignant stricture of the bile duct and pancreatic duct stenting following sphincterotomy for type 2 sphincter of Oddi dysfunction.
Introduction: Irritable bowel syndrome (IBS) is the most common referral to a gastroenterologist.The prevalence is between 14% to 24% in women and 5% to 19% in men in the US and Britain. It cost US $1.6 billion in 1998 mostly in medication and diagnostic tests. While volumes have been written, which make stimulating reading, on the pathogenesis of IBS namely brain gut neural dysfunction, visceral hypersensitivity, sympathetic and parasympathetic imbalance, role of gut infection etc., purpose of this review is to focus on practical management of IBS.
Five year survival of oesophageal cancers is approximately 10% globally. Early cancers are operable. Of the two types of oesophageal cancers we see, incidence of squamous cell carcinomas (SCC) is declining while there is progressive rise of the incidence of the adenocarcinoma (AC) of the oesophagus. This article focuses on the identification of at risk individuals.
The poor outcome of pancreatic cancer (PC) is reflected by the overall less than 5% five year survival. Eighteen hundred people are diagnosed with PC every year in Australia. Approximately 33,730 new cases were expected to be diagnosed in USA in 2006 with 32,300 expected deaths. Mortality closely follows incidence as demonstrated in the 2002 Australian graph (page 2). However, appropriate attention to certain risk factors has the potential to reduce mortality by early diagnosis. Pancreatic cancer is rare before the age of 45 and slightly more common in the male than in the female (1.3:1).
Hereditary Haemochromatosis (HH) is a common autosomal recessive disorder occurring at a frequency of 1 in 200-250 among Anglo-Celtic Caucasian population in Australia. Most general practices, depending on the size, will have few to several of these patients . Most patients present with abnormal iron studies and or elevated liver tests and some with family history and can be managed at the general practice .
Colorectal cancer(CRC) is the 2nd leading cause of cancer death in Australia following lung cancer. CRC will develop in 5-6% of the adult population without family history and half will die as a consequence. Hence the importance for screening for CRC. Following table summarises risk groups and screening methods.